Deals
Lilly Buys Pet Vaccines From Boehringer for $885 Million
- Purchase brings rabies, bordetella shots for Elanco unit
- Sale of Boehringer site, vaccine required for Merial purchase
This article is for subscribers only.
Eli Lilly & Co. will buy a set of animal-health products from Boehringer Ingelheim GmbH’s Vetmedica unit for $885 million, including its U.S. portfolio of feline, canine and rabies vaccines and an Iowa-based manufacturing site.
The deal is the 10th for Lilly’s Elanco animal-health unit since 2007, and the unit’s first major acquisition of pet vaccines during that time. It will add eight product lines, including routine vaccines for bordetella, Lyme disease, rabies and parvovirus, Indianapolis-based Lilly said Wednesday in a statement.